These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1394 related articles for article (PubMed ID: 27909164)

  • 1. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
    Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL
    J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
    Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
    Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S
    J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
    Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
    Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.
    Malone TC; Mennenga SE; Guss J; Podrebarac SK; Owens LT; Bossis AP; Belser AB; Agin-Liebes G; Bogenschutz MP; Ross S
    Front Pharmacol; 2018; 9():256. PubMed ID: 29666578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
    de la Salle S; Kettner H; Thibault Lévesque J; Garel N; Dames S; Patchett-Marble R; Rej S; Gloeckler S; Erritzoe D; Carhart-Harris R; Greenway KT
    Sci Rep; 2024 Jul; 14(1):16524. PubMed ID: 39019922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L
    JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
    Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():1-10. PubMed ID: 28947181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
    Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
    Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
    Ross S
    Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
    Griffiths RR; Richards WA; McCann U; Jesse R
    Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
    Bhagavan C; Glue P; Evans W; Reynolds L; Turner T; King C; Russell BR; Morunga E; Mills JL; Layton G; Menkes DB
    Trials; 2024 May; 25(1):336. PubMed ID: 38773523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
    Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M
    J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 70.